Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person9
Lipocine Inc.
Company
Rapid Line Inc.
Company
VALUE LINE INC
Company
LiveOne, Inc.
Company
Lineage, Inc.
Company
LifeMD, Inc.
Company
Life360, Inc.
Company
Medline Inc.
Company
Eva Live Inc
Company
Primary record11
Lipocine Inc. filed 8-K
Item 2.02 Results of Operations and Financial Condition. On November 5, 2026, the Company issued a press release announcing financial and operational results for the quarter ended September 30, 2026. A copy of this press
Lipocine Inc. filed 8-K
Item 8.01 Other Events The Company has updated its corporate presentation that it uses when meeting with investors, analysts and others. The presentation is filed as Exhibit 99.1. Item 9.01 Financial Statements and Exhib
Lipocine Inc. filed 8-K
Item 8.01 Other Events On October 7, 2026, the Company announced that Health Canada had approved TLANDO for testosterone replacement therapy in adult males. A copy of the press release is furnished as Exhibit 99.1 to thi
Lipocine Inc. filed 4
SEC form 4 filed by Lipocine Inc. (CIK 1535955) on 2026-10-01.
Lipocine Inc. filed 4
SEC form 4 filed by Lipocine Inc. (CIK 1535955) on 2026-09-30.
Lipocine Inc. filed 8-K
Item 8.01 Other Events On September 16, 2026, the Company presented at H.C. Wainwright 28 th Annual Global Investor Conference which was being held September 14 16, 2026, in New York City, NY. A copy of the presentation
Lipocine Inc. filed 8-K
Item 8.01 Other Events On September 14, 2026, the Company issued a press release announcing the initiation of its BLOOM Phase 3 Study of LPCN 1154 for postpartum depression. A copy of the press release is furnished as Ex
Lipocine Inc. filed 8-K
Item 8.01. Other Events. On September 8, 2026, Lipocine Inc. (the Company ) and A.G.P./Alliance Global Partners (the Sales Agent ) agreed that the Sales Agent s fee on sales made under that certain Sales Agreement dated
Lipocine Inc. filed 8-K
Item 8.01 Other Events On September 10, 2026, the Company issued a press release announcing that it is presenting and meeting with investors at the H.C. Wainwright 28 th Annual Global Investor Conference held September 1
Lipocine Inc. filed SCHEDULE 13G/A
, as amended, Squadron Capital Management, LLC and Mr. Sesterhenn and Mr. Blank expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be
Lipocine Inc. filed 4
SEC form 4 filed by Lipocine Inc. (CIK 1535955) on 2026-08-07.